Journal
TRENDS IN BIOTECHNOLOGY
Volume 27, Issue 11, Pages 628-635Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2009.07.009
Keywords
-
Categories
Funding
- Grant Agency of the Academy of Sciences of the Czech Republic [KAN200100801 BIOKOM]
- Grant Agency of the Czech Republic [305/09/H008]
- Ministry of Education [6046137305]
Ask authors/readers for more resources
Varied therapeutic peptides and proteins represent a rapidly growing part of marketed drugs and have an undisputed place alongside other established therapies. Nevertheless, such biodrugs have several drawbacks that hinder their therapeutic application. These are undesirable physicochemical properties, such as variable solubility, low bioavailability and limited stability. These issues can be overcome by addition of stabilizing agents and directed injectable administration, which can however result in low patient compliance. Hence, there is a drive in the biotechnology industry to produce needle-free and more user-friendly drugs, and this has led to the growth of nano-enabled drug delivery systems in the last decade. As discussed here, nanobiotechnology is becoming a commercially feasible and promising opportunity for oral, pulmonary and transdermal administration routes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available